Allergen immunotherapy for asthma

Michael J Abramson; Robert M Puy; John M Weiner

doi:10.1002/14651858.CD001186

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Guías
Temas

Revisiones y protocolos relacionados

Topics

Temas

Figure 1

Of every 100 asthma patients treated with immunotherapy, 30 patients will be prevented from having an attack (worse symptoms), 40 would not have had an attack anyway and 30 will still have an attack. In other words, about 4 patients have to be treated to prevent one attack of asthma.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 Allergen immunotherapy versus placebo, Outcome 1 Asthma symptom scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Allergen immunotherapy versus placebo, Outcome 2 Symptomatic deterioration.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Allergen immunotherapy versus placebo, Outcome 3 Asthma medication scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 Allergen immunotherapy versus placebo, Outcome 4 Increased asthma medication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 Allergen immunotherapy versus placebo, Outcome 5 Lung function parameters.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 Allergen immunotherapy versus placebo, Outcome 6 Deterioration in lung function.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 Allergen immunotherapy versus placebo, Outcome 7 Nonspecific BHR indices.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 Allergen immunotherapy versus placebo, Outcome 8 Increased nonspecific BHR.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.9

Comparison 1 Allergen immunotherapy versus placebo, Outcome 9 Allergen specific BHR indices.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.10

Comparison 1 Allergen immunotherapy versus placebo, Outcome 10 Increased allergen specific BHR.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 Allergen immunotherapy versus antigenically inactive control, Outcome 1 Asthma symptom scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.2

Comparison 2 Allergen immunotherapy versus antigenically inactive control, Outcome 2 Symptomatic deterioration.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.3

Comparison 2 Allergen immunotherapy versus antigenically inactive control, Outcome 3 Increased asthma medication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.1

Comparison 3 House dust versus placebo, Outcome 1 Symptomatic deterioration.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.2

Comparison 3 House dust versus placebo, Outcome 2 Increased asthma medication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.3

Comparison 3 House dust versus placebo, Outcome 3 Deterioration in lung function.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.4

Comparison 3 House dust versus placebo, Outcome 4 Increased allergen specific BHR.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.1

Comparison 4 Allergen immunotherapy versus untreated control, Outcome 1 Asthma symptom scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.2

Comparison 4 Allergen immunotherapy versus untreated control, Outcome 2 Asthma medication scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.3

Comparison 4 Allergen immunotherapy versus untreated control, Outcome 3 Lung function parameters.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.4

Comparison 4 Allergen immunotherapy versus untreated control, Outcome 4 Nonspecific BHR indices.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.5

Comparison 4 Allergen immunotherapy versus untreated control, Outcome 5 Allergen specific BHR indices.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.6

Comparison 4 Allergen immunotherapy versus untreated control, Outcome 6 Increased allergen specific BHR.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 5.1

Comparison 5 Allergen immunotherapy versus Inhaled steroid, Outcome 1 Asthma symptom scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 5.2

Comparison 5 Allergen immunotherapy versus Inhaled steroid, Outcome 2 Deterioration in FEV1.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. Allergen immunotherapy versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Asthma symptom scores Show forest plot	27	1064	Std. Mean Difference (IV, Random, 95% CI)	‐0.72 [‐0.99, ‐0.44]

1.1 Mite immunotherapy	9	304	Std. Mean Difference (IV, Random, 95% CI)	‐0.78 [‐1.27, ‐0.29]
1.2 Pollen immunotherapy	14	547	Std. Mean Difference (IV, Random, 95% CI)	‐0.66 [‐0.99, ‐0.33]
1.3 Other immunotherapy	5	213	Std. Mean Difference (IV, Random, 95% CI)	‐0.83 [‐1.92, 0.26]
2 Symptomatic deterioration Show forest plot	22	1112	Risk Ratio (M‐H, Random, 95% CI)	0.51 [0.41, 0.65]

2.1 Mite immunotherapy	12	460	Risk Ratio (M‐H, Random, 95% CI)	0.62 [0.44, 0.87]
2.2 Pollen immunotherapy	3	220	Risk Ratio (M‐H, Random, 95% CI)	0.25 [0.07, 0.90]
2.3 Animal dander immunotherapy	4	107	Risk Ratio (M‐H, Random, 95% CI)	0.47 [0.24, 0.92]
2.4 Other immunotherapy	3	325	Risk Ratio (M‐H, Random, 95% CI)	0.46 [0.33, 0.65]
3 Asthma medication scores Show forest plot	14	608	Std. Mean Difference (IV, Random, 95% CI)	‐0.80 [‐1.13, ‐0.48]

3.1 Mite immunotherapy	8	242	Std. Mean Difference (IV, Random, 95% CI)	‐1.06 [‐1.61, ‐0.52]
3.2 Pollen immunotherapy	6	245	Std. Mean Difference (IV, Random, 95% CI)	‐0.69 [‐1.16, ‐0.21]
3.3 Other immunotherapy	1	121	Std. Mean Difference (IV, Random, 95% CI)	‐0.26 [‐0.62, 0.10]
4 Increased asthma medication Show forest plot	16	564	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.58, 0.76]

5 Lung function parameters Show forest plot	16		Std. Mean Difference (IV, Random, 95% CI)	Subtotals only

5.1 Peak Expiratory Flow	8	406	Std. Mean Difference (IV, Random, 95% CI)	0.04 [‐0.45, 0.53]
5.2 FEV1	6	174	Std. Mean Difference (IV, Random, 95% CI)	‐0.13 [‐0.83, 0.57]
5.3 Thoracic Gas Volume	2	81	Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
6 Deterioration in lung function Show forest plot	7	253	Risk Ratio (M‐H, Random, 95% CI)	0.89 [0.73, 1.10]

7 Nonspecific BHR indices Show forest plot	15	471	Std. Mean Difference (IV, Random, 95% CI)	‐0.43 [‐0.71, ‐0.14]

7.1 LogPD20 Methacholine	9	348	Std. Mean Difference (IV, Random, 95% CI)	‐0.33 [‐0.66, ‐0.00]
7.2 LogPC20 Histamine	4	76	Std. Mean Difference (IV, Random, 95% CI)	‐0.55 [‐1.37, 0.28]
7.3 LogPC35 Acetylcholine	1	21	Std. Mean Difference (IV, Random, 95% CI)	‐1.29 [‐2.28, ‐0.31]
7.4 DeltaFEV1% Cold air	1	26	Std. Mean Difference (IV, Random, 95% CI)	‐0.52 [‐1.31, 0.26]
8 Increased nonspecific BHR Show forest plot	5	121	Risk Ratio (M‐H, Fixed, 95% CI)	0.48 [0.33, 0.72]

9 Allergen specific BHR indices Show forest plot	15	436	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.66 [‐0.87, ‐0.45]

9.1 LogPD20 Mite	5	115	Std. Mean Difference (IV, Fixed, 95% CI)	‐1.14 [‐1.62, ‐0.65]
9.2 LogPD20 Pollen	2	107	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.69 [‐1.09, ‐0.30]
9.3 LogPD20 Animal dander	6	153	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.61 [‐0.95, ‐0.27]
9.4 LogPD20/PC100 Other allergens	2	61	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.18 [‐0.70, 0.33]
10 Increased allergen specific BHR Show forest plot	16	430	Risk Ratio (M‐H, Fixed, 95% CI)	0.51 [0.41, 0.63]

Comparison 1. Allergen immunotherapy versus placebo

Ir a la tabla de la revisión

Comparison 2. Allergen immunotherapy versus antigenically inactive control

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Asthma symptom scores Show forest plot	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

2 Symptomatic deterioration Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

3 Increased asthma medication Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

Comparison 2. Allergen immunotherapy versus antigenically inactive control

Ir a la tabla de la revisión

Comparison 3. House dust versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptomatic deterioration Show forest plot	3	162	Risk Ratio (M‐H, Fixed, 95% CI)	0.53 [0.21, 1.35]

2 Increased asthma medication Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

3 Deterioration in lung function Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

4 Increased allergen specific BHR Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

Comparison 3. House dust versus placebo

Ir a la tabla de la revisión

Comparison 4. Allergen immunotherapy versus untreated control

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Asthma symptom scores Show forest plot	3	200	Std. Mean Difference (IV, Random, 95% CI)	‐1.84 [‐3.21, ‐0.47]

2 Asthma medication scores Show forest plot	1		Std. Mean Difference (IV, Fixed, 95% CI)	Totals not selected

3 Lung function parameters Show forest plot	2	164	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.80 [‐1.21, ‐0.39]

4 Nonspecific BHR indices Show forest plot	1		Std. Mean Difference (IV, Fixed, 95% CI)	Totals not selected

5 Allergen specific BHR indices Show forest plot	2	50	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.62 [‐1.22, ‐0.01]

6 Increased allergen specific BHR Show forest plot	1		Peto Odds Ratio (Peto, Fixed, 95% CI)	Totals not selected

Comparison 4. Allergen immunotherapy versus untreated control

Ir a la tabla de la revisión

Comparison 5. Allergen immunotherapy versus Inhaled steroid

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Asthma symptom scores Show forest plot	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

2 Deterioration in FEV1 Show forest plot	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

Comparison 5. Allergen immunotherapy versus Inhaled steroid

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet